STI Pharma Gets Letter for Deficiencies in Reporting Adverse Events

Drug GMP Report
A A
The FDA issued a warning letter to STI Pharma for serious violations of Postmarketing Adverse Drug Experience (PADE) reporting requirements.

To View This Article:

Login

Subscribe To Drug GMP Report